secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEOGENOMICS INC (NEO)
CIK:        0001077183
Form:       8-K
Filed at:   2026-07-28T20:05:51+00:00
Accession:  0001077183-26-000058
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeoGenomics Q2 revenue up 11% to $202M; raises FY2026 guidance; settles DOJ matter
--------------------------------------------------------------------------------

- Total revenue $202M (+11% YoY); clinical revenue $187M (+14%); NGS revenue +26%.
- GAAP net income $2M (incl. $11M debt extinguishment gain) vs net loss $45M in Q2 2025.
- Adjusted EBITDA $14M (+36% YoY); company raises full-year 2026 revenue and adjusted EBITDA guidance.
- Completed $316M 0.75% convertible notes due 2032; repurchased $276M of existing 0.25% notes and $25M of common stock.
- Finalized civil settlement with DOJ regarding consulting services; self-disclosed matter resolved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1077183/000107718326000058/0001077183-26-000058-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1077183/000107718326000058/neo-20260728.htm
  HTML page:      https://secwatch.observer/filing/0001077183-26-000058

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer